Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Qrem is a regenerative medicine company based in Barcelona that specializes in point-of-care autologous therapies. The company has developed the Q-REM Cytokine, a portable "lab-in-a-box" medical device designed to produce cytokine-rich serum (ACS) from a patient's own blood in approximately 30 minutes. This autologous serum contains high concentrations of anti-inflammatory proteins, specifically Interleukin-1 receptor antagonist (IL-1Ra), which is used to treat osteoarthritis and other musculoskeletal conditions. By automating complex laboratory processes into a simple bedside procedure, Qrem enables clinicians to provide personalized regenerative treatments that reduce pain and improve joint function without the need for external lab processing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Tecnologia Regenerativa Qrem.